PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Symptom | C0005940|bone disease |
| Sentences | 8 |
| PubMedID- 22158495 | Multi-field-of-view spect is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. |
| PubMedID- 22373838 | Denosumab, a monoclonal antibody against receptor activator of nuclear factor-kb ligand, was shown to be superior to zoledronic acid for prevention of skeletal-related events in prostate cancer patients with metastatic bone disease. |
| PubMedID- 23049248 | This article reviews the problem of bone disease in prostate cancer and the evolving role of the novel agent denosumab, a fully human monoclonal antibody that inhibits the receptor activator of nuclear factor-kappab ligand, in suppressing bone resorption and offering bone protection in this disease. |
| PubMedID- 20398032 | bone disease in prostate cancer. |
| PubMedID- 20038858 | Conclusion: bone markers are remarkably elevated in the serum of prostate cancer patients with metastatic bone disease and correlate with eod. |
| PubMedID- 21744161 | Furthermore, it has been recently shown to prevent skeletal-related events in prostate cancer patients with metastatic bone disease. |
| PubMedID- 21498309 | The ct flare response of metastatic bone disease in prostate cancer. |
| PubMedID- 21188095 | S-alp is a recognized marker of metastatic bone disease in patients with prostate cancer.40 in both treatment arms, higher baseline testosterone led to slower achievement of castrate testosterone levels; however, achievement of castrate levels occurred significantly faster with degarelix than with leuprolide for all testosterone subgroups.41 reduction in psa levels was also significantly faster with degarelix than leuprolide in all testosterone subgroups (p < 0.0001). |
Page: 1